New High Dose CBD Formulations Developed As CBD Market Flourishes
VANCOUVER, BC and LAS VEGAS – (CSE: OVAT) (OTCQB: OVATF) – Ovation Science Inc. (“Ovation” or the “Company”), a topical and transdermal cannabis product development company with a patented skin delivery technology and backed by over twenty years of research and development, announces that it has developed new high dose CBD (Cannabidiol) formulations for both its “health and wellness” and its “beauty” lines. Although Ovation also has highly effective formulations that contain THC (Tetrahydrocannabinol), Ovation formulates its CBD-only product from US grown hemp which contain no THC and therefore has no psycho active effects.
“Ovation is a cannabis research and development company and although we have over twenty-five topical formulations already developed including THC, CBD and combinations of the two, we wanted to expand the dosage range of our CBD formulations. We are very pleased to have developed a CBD transdermal cream formulation with 1500mg of CBD per ounce (per 30ml) which would give a consumer a 3000mg jar of transdermal CBD cream,” said Terry Howlett, CEO of Ovation Science. “Additionally we have also formulated our beauty line with 200mg per ounce (per 30ml) for the anti-aging day and night creams and 2000mg for our body lotion (4 ounce bottle).” He added, “We believe that high dose CBD topicals are the future, particularly as consumers keep experiencing the benefit of using topical CBD (and THC) creams and lotions. We believe there is a demand for high dose CBD topicals and transdermal creams and we are excited to explore these new opportunities further with potential licensees.”
CBD is believed to have a range of positive health benefits and therefore its popularity continues to grow amongst consumers. According to a ResearchAndMarkets.com February 2021 report, CBD derived from hemp, is expected to grow at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028 owing to increasing demand and rising awareness. There are different products formats that consumers can use however CBD topicals can be an easy, simple alternative for consumers trying CBD for the first time. There is no universal dosage of CBD that is published. Consumers should discuss options with their healthcare provider as every person is different and it can be dependent on current medications, body weight, and other factors. Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.
Ovation’s licensee for Nevada sells the Company’s Invisicare® powered CBD and CBD/THC combo formulations to dispensaries across Nevada. The Company previously announced that these Ovation topical products formulations are in the top 5 in sales in Nevada dispensaries according to Headset.io. Ovation is prepared to duplicate this success and is seeking licensees in the other thirty-six approved states to implement this plan.
Ovation Science Inc. is a research and development company that licenses its topical and transdermal cannabis formulations made with its proprietary Invisicare® skin delivery technology and targets cannabis companies globally. The technology enhances the delivery of cannabidiol (CBD) and tetrahydrocannabinol (THC) to and through the skin. Ovation management has over twenty years of topical drug delivery experience and has leveraged this experience and technology to develop a series of topical and transdermal cannabis products. Ovation’s products have many advantages over cannabis products that are smoked or ingested including avoiding the side-effects from smoking and eliminating the first pass effect through the liver (which reduces the amount of CBD / THC available and increasing the onset time).
For information about Ovation Science Inc. visit www.ovationscience.com
Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including its CBD/THC cannabis formulations which are licensed out and also distributed under Ovation’s own brands; ARLO CBD Beauty and InVibe® MD (“health & wellness” line), and secondly, its unique DermSafe® hand sanitizer; all made with its patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents, and proprietary formulations which cannot be duplicated. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees along with revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT and in the USA on OTC Markets under the symbol OVATF. Visit our website www.ovationscience.com for more information.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of continued sales or expansion of distribution to other states or continued sales in dispensaries or in retail markets. There is no guarantee that consumers will purchase high dose products. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
- Commentary: It’s time for Biden to keep his promises on cannabisPaul Armentano, the deputy director of the National Organization for the Reform of Marijuana Laws (NORML), calls on President Joe Biden to live up to the pledges made during his campaign regarding cannabis legalization.
- Unofficial totals show Missouri cannabis legalization initiative shortAn initiative to legalize recreational marijuana use in Missouri will need help if it is going to be on the November ballot. Reports from every county in the state show the petition is short of its goal in two of the six congressional districts needed to qualify for the ballot.
- Fate of Missouri cannabis initiative unclear as signature count continuesWhether Missouri voters will get a chance to legalize recreational marijuana in November is still in question. The latest incomplete tabulations show the Legal Missouri 2022 initiative is short of the necessary signatures in four of the six Congressional districts necessary to make the ballot.
- ACLU of NV suit to deschedule cannabis statewide survives challengeA legal effort by the ACLU of Nevada to force the Nevada Board of Pharmacy to remove cannabis from its Schedule 1 of controlled substances will proceed, Clark County Judge Joe Hardy ruled Wednesday when he denied the board’s motion to dismiss the ACLU’s lawsuit.
- Advocates, parents ‘beg’ Nebraskans to seek out and sign petition to legalize medical cannabisAdvocates for legalizing medical marijuana switched Wednesday from urging Nebraskans to sign their petition to begging them as a July 7 deadline looms to submit signatures to qualify for the ballot in November.
- Iowans launch cannabis reform campaign aimed at showing public supportRobert “Lewy” Lewis of Windsor Heights has been in pain since 1974, when he had spinal surgery at the age of 21. To repair a blockage in his spine, surgeons removed eight inches of his vertebrae and then sewed them back on, using about 300 steel stitches.
- Big Apple Cannabis: CWCB Returns to New York City for Eighth Year“No one seems to have gotten it right.” Mayor Eric Adams told a Friday afternoon crowd, of legal cannabis in America. “This is our chance to get it right.” New York City’s mayor addressed attendees of the 2022 Cannabis World Congress & Business Expo (CWCBExpo) on the second day of the three-day event. Adams stressed the social equity focus of New York’s cannabis program.
- Nebraska medical cannabis backers file legal challenge to petition processSupporters of medical marijuana in Nebraska have launched a legal challenge to the state’s requirement that 5% of registered voters in at least 38 counties sign a petition to get the measure before voters on the ballot.
- N.J. lawmakers seek to curb cannabis useAs New Jersey nears the end of its first month of legal recreational marijuana sales, lawmakers have introduced a series of bills aimed at restricting what types of workers can use cannabis off the job.
- Missouri House votes to require disclosure of medical cannabis ownership recordsThe Missouri House voted overwhelmingly Tuesday to require state regulators to disclose ownership information for businesses granted medical marijuana licenses that the state has withheld from public view.